Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 5/20 | 0.70 |
| ▸ | DRD3 | P35462 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 2/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.54 |
| ▸ | HRH1 | P35367 | 1/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.54 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4240820 | 0.94 | DRD2 (0.64) | DRD2DRD3KDM4EGAAHTR7 | |
| SCHEMBL13079493 | 0.90 | DRD2 (0.68) | DRD2DRD3KDM4EGAAHTR7 | |
| SCHEMBL29094360 | 0.87 | KDM4E (0.58) | DRD2DRD3KDM4EGAAHTR7 | |
| SCHEMBL5356200 | 0.85 | KDM4E (0.62) | DRD2DRD3KDM4EGAAHTR7 | |
| SCHEMBL3206275 | 0.83 | CYP2D6 (0.58) | DRD2DRD3KDM4EHTR7HRH3 | |
| SCHEMBL7487458 | 0.83 | HRH3 (0.53) | DRD2DRD3KDM4EHTR7HRH3 | |
| SCHEMBL1714712 | 0.82 | HRH3 (0.77) | DRD2DRD3HRH3HRH1SIGMAR1 | |
| SCHEMBL18396586 | 0.82 | HRH3 (0.52) | DRD2DRD3KDM4EHTR7HRH3 | |
| SCHEMBL6135057 | 0.81 | HRH3 (0.57) | DRD2DRD3KDM4EGAAHTR7 | |
| SCHEMBL6135382 | 0.81 | HRH3 (0.57) | DRD2DRD3KDM4EGAAHTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| EP-1879887-A2 | NPY ANTAGONISTS, PREPARATION AND USE | Cerep (FR) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006108965-A2 | NPY ANTAGONISTS, PREPARATION AND USE | CEREP (FR) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | DRD2 337/4885DRD3 384/4885KDM4E 1604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.